The corona vaccine that is being developed by Janssen Vaccines from Leiden, a subsidiary of the American pharmaceutical company Johnson & Johnson, is entering a large-scale test phase. In the so-called third test phase, tens of thousands of volunteers are administered the drug to monitor side effects.
The corona vaccine that is being developed by Janssen Vaccines from Leiden, a subsidiary of the American pharmaceutical company Johnson & Johnson, is entering a large-scale test phase. In the so-called third test phase, tens of thousands of volunteers are administered the drug to monitor side effects.
The European Union has ordered hundreds of millions of doses of the drug, but has also purchased hundreds of millions of doses from other vaccine developers. Some resources have already entered a large-scale test phase.
Johnson & Johnson aims to test at least 60,000 people over the age of 18 in the United States, South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. All countries have been statistically severely affected by the COVID-19 outbreak.
The test phase must be completed within two months. Johnson & Johnson hopes to publish results at the end of this year or early next year.
Johnson & Johnson aims to produce a billion doses next year
The pharmaceutical company hopes to be able to test large numbers of elderly people. If the test results are again promising, Johnson & Johnson wants to take the next step in the production process. Next year, the American company wants to develop a billion doses.
Experts are hopeful about the Johnson & Johnson vaccine, partly because the company is focusing on one dose instead of the regular two doses, as with AstraZeneca, for example.
Using one dose only allows interested parties to schedule one appointment to be vaccinated, and also simplifies the worldwide distribution of the drug. The vaccine would also have a better shelf life.
